Rob Lin, PhD, CFA

Rob Lin, PhD, CFA has a diverse work experience in various leadership roles within the healthcare industry. Currently, they are the Chief Executive Officer at Avista Therapeutics, a position they have held since October 2021. Prior to this, they served as the Board Director and Former Founding CEO at BlueSphere Bio starting from September 2018.

Earlier in their career, Rob was a Vice President at UPMC Enterprises, where they played a crucial role in investing in life sciences startups through the UPMC Immune Transplant and Therapy Center (ITTC). Rob was responsible for exploring future opportunities for investment in areas such as immuno-oncology, transplant, aging, and vision. Additionally, they performed interim CEO functions for a startup launched with ITTC funding.

Rob also served as a Chief Financial Officer at Phlebotics from July 2016 to September 2017, where they showcased their financial expertise. Prior to this, they were the Vice President of Finance at the Infectious Disease Research Institute, overseeing financial grant reporting and budget planning.

Earlier in their career, Rob worked at the Bill & Melinda Gates Foundation as the Deputy Director of FP&A, Global Health. Rob provided financial leadership to the Global Health Program and served as an active member of the executive committee.

Rob's work experience also includes roles at Millennium Pharmaceuticals, where they served as a Senior Manager in corporate finance and strategy development. Rob utilized their scientific knowledge and financial skills to evaluate strategic alternatives and potential investment opportunities.

Overall, Rob Lin, PhD, CFA has demonstrated strong leadership, financial expertise, and a deep understanding of the healthcare industry throughout their career.

Rob Lin, PhD, CFA, obtained their Bachelor of Science degree in Biological Sciences from Stanford University, where they also earned a Master of Science degree in Chemical Engineering. Following this, they attended Harvard Medical School and completed a Master of Medical Sciences degree. Continuing their education at Harvard University, they earned a PhD in Human Genetics. In 2003, Rob Lin became a Chartered Financial Analyst® (CFA) Charterholder through the CFA Institute.